S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:ALEC

Alector (ALEC) Stock Forecast, Price & News

$6.88
+0.85 (+14.10%)
(As of 09/22/2023 ET)
Compare
Today's Range
$6.28
$6.93
50-Day Range
$5.20
$8.77
52-Week Range
$4.98
$10.07
Volume
1.11 million shs
Average Volume
580,559 shs
Market Capitalization
$576.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.89

Alector MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
116.4% Upside
$14.89 Price Target
Short Interest
Bearish
9.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.42mentions of Alector in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3.07 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.85) to ($2.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

506th out of 968 stocks

Biological Products, Except Diagnostic Industry

74th out of 160 stocks


ALEC stock logo

About Alector (NASDAQ:ALEC) Stock

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

ALEC Price History

ALEC Stock News Headlines

Analyst Expectations for Alector's Future
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Alector (ALEC) Receives a Buy from Mizuho Securities
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
H.C. Wainwright Sticks to Its Buy Rating for Alector (ALEC)
Alector to Host Mid-Year Earnings Conference Call
Alector (NASDAQ: ALEC)
Alector (ALEC) Investor Presentation - Slideshow
See More Headlines
Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

ALEC Company Calendar

Last Earnings
8/03/2023
Today
9/22/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALEC
Fax
N/A
Employees
239
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$14.89
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+122.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-133,310,000.00
Net Margins
-140.18%
Pretax Margin
-136.51%

Debt

Sales & Book Value

Annual Sales
$133.62 million
Book Value
$2.59 per share

Miscellaneous

Free Float
72,094,000
Market Cap
$559.98 million
Optionable
Not Optionable
Beta
0.75

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Arnon Rosenthal Ph.D. (Age 67)
    Co-Founder, CEO & Director
    Comp: $1.02M
  • Dr. Sara Kenkare-Mitra Ph.D. (Age 55)
    Pres and Head of R&D
    Comp: $1.19M
  • Dr. Marc Grasso M.D. (Age 50)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $738.05k
  • Dr. Gary Romano M.D. (Age 61)
    Ph.D., Chief Medical Officer
    Comp: $602.98k
  • Mr. Peter Heutink Ph.D.
    Chief Scientific Officer
  • Ms. Danielle Pasqualone J.D.
    Ph.D., Gen. Counsel
  • Erica Jefferson
    VP of Communications & Public Affairs
  • Michelle Corral
    VP of Communications & Investor Relations
  • Ms. Clare Hunt M.B.A.
    Chief People Officer
  • Ms. Kristina Cutter M.P.H.
    Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer













ALEC Stock - Frequently Asked Questions

Should I buy or sell Alector stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALEC shares.
View ALEC analyst ratings
or view top-rated stocks.

What is Alector's stock price forecast for 2023?

8 Wall Street research analysts have issued 12-month target prices for Alector's stock. Their ALEC share price forecasts range from $8.00 to $41.00. On average, they expect the company's share price to reach $14.89 in the next year. This suggests a possible upside of 122.9% from the stock's current price.
View analysts price targets for ALEC
or view top-rated stocks among Wall Street analysts.

How have ALEC shares performed in 2023?

Alector's stock was trading at $9.23 at the start of the year. Since then, ALEC shares have decreased by 27.6% and is now trading at $6.68.
View the best growth stocks for 2023 here
.

When is Alector's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ALEC earnings forecast
.

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) announced its quarterly earnings results on Thursday, August, 3rd. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.81) by $0.83. The business earned $56.21 million during the quarter, compared to the consensus estimate of $3.63 million. Alector had a negative net margin of 140.18% and a negative trailing twelve-month return on equity of 67.57%.

What ETF holds Alector's stock ?

iShares Neuroscience and Healthcare ETF holds 7,557 shares of ALEC stock, representing 1.22% of its portfolio.

What guidance has Alector issued on next quarter's earnings?

Alector issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $90.00 million-$100.00 million, compared to the consensus revenue estimate of $29.07 million.

What is Arnon Rosenthal's approval rating as Alector's CEO?

4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

When did Alector IPO?

(ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Who are Alector's major shareholders?

Alector's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.34%), Braidwell LP (4.93%), State Street Corp (3.24%), JPMorgan Chase & Co. (2.86%), Point72 Asset Management L.P. (2.07%) and Franklin Resources Inc. (1.92%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller, Robert King, Robert Paul, Sara Kenkare-Mitra and Shehnaaz Suliman.
View institutional ownership trends
.

How do I buy shares of Alector?

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $6.68.

How much money does Alector make?

Alector (NASDAQ:ALEC) has a market capitalization of $559.98 million and generates $133.62 million in revenue each year. The company earns $-133,310,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.

How many employees does Alector have?

The company employs 239 workers across the globe.

Does Alector have any subsidiaries?
The following companies are subsidiares of Alector: Alector LLC.
Read More
How can I contact Alector?

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at ir@alector.com.

This page (NASDAQ:ALEC) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -